How Stanozolol (Winstrol) Affects ALT

Stanozolol (Winstrol) is a 17-alpha-alkylated derivative of dihydrotestosterone (DHT) with moderate hepatotoxic properties:

1. C17-aa structure: Like all 17-alpha-alkylated steroids, stanozolol resists hepatic first-pass metabolism, exposing the liver to high concentrations of active compound.
2. Cholestatic component: Stanozolol impairs bile salt transport, though typically to a lesser degree than oxymetholone or superdrol.
3. Hepatocellular stress: Direct hepatocyte membrane damage releases ALT, though stanozolol causes less outright hepatocellular necrosis than more hepatotoxic orals.
4. DHT derivative: As a DHT-based compound, stanozolol does not aromatise and has strong androgenic properties. Its hepatotoxicity profile is considered moderate relative to other C17-aa steroids.

Notable characteristic: Stanozolol is arguably more damaging to lipids than to the liver. It dramatically suppresses HDL cholesterol (often more than other oral steroids at equivalent doses) and elevates LDL, making cardiovascular risk a greater concern than hepatotoxicity for many users.

Typical oral doses (25-50 mg/day):

• ALT rises 2-4x ULN (80-160 U/L)
• AST rises proportionally
• GGT and ALP may be mildly elevated
• Bilirubin usually remains normal at standard doses

Higher doses (75-100 mg/day):

• ALT can reach 3-6x ULN (120-240+ U/L)
• Cholestatic features become more prominent
• These doses are less common and generally unnecessary

Injectable stanozolol (Winstrol Depot):

• The injectable form still carries hepatotoxicity because stanozolol retains its C17-aa structure regardless of route
• However, bypassing first-pass hepatic metabolism may result in slightly lower ALT elevations at equivalent doses
• The injectable form is not liver-safe; it simply has a marginally reduced hepatic impact

Timeline: ALT elevation begins within the first week and typically peaks at weeks 3-5. Stanozolol cycles commonly run 6-8 weeks, with liver stress accumulating throughout.

Pre-cycle: Baseline liver panel and lipid panel. Stanozolol affects both, and lipid monitoring is equally important.

On cycle: Check liver enzymes and lipids at week 4.

Post-cycle: Recheck at 4 weeks post-discontinuation.

Key point: While monitoring ALT is important, the greater clinical concern with stanozolol is its lipid impact. HDL suppression of 40-50% is typical, and this carries more long-term cardiovascular risk than transient ALT elevation.

Cessation triggers:

• ALT exceeding 5x ULN
• Clinical signs of cholestasis
• Severe lipid deterioration (HDL below 20 mg/dL) may also warrant discontinuation

Liver support:

• TUDCA 500-750 mg/day (moderate dose sufficient for stanozolol's moderate hepatotoxicity)
• NAC 600-1200 mg/day
• Standard liver support stack is adequate; aggressive high-dose protocols are not typically needed

Cycle design:

• Limit stanozolol cycles to 6-8 weeks
• Oral doses of 25-50 mg/day are standard; higher doses add minimal benefit with increased toxicity
• Do not stack with other C17-aa oral steroids
• Many bodybuilders use stanozolol only during the final weeks of contest preparation

Lipid protection (equally important):

• Cardiovascular exercise 150+ minutes per week
• Omega-3 fatty acids 3-5 g EPA/DHA daily
• Citrus bergamot 500-1000 mg/day
• Monitor lipids closely; stanozolol is one of the most lipid-destructive oral steroids

Post-cycle: Allow 6-8 weeks of liver and lipid recovery before using any other oral steroid. Continue cardio and omega-3 supplementation throughout recovery.